Ovarian

MaxCyte Receives US FDA Investigational New Drug Clearance for First Clinical Program

(MaxCyte) July 16, 2018 - MaxCyte announced that it has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to begin a clinical study in the United States with its first wholly-owned chimeric antigen receptor (CAR) therapeutic candidate, MCY-M11.

read corporate press release

Jury Orders J&J to Pay $4.7 Billion in Missouri Asbestos Cancer Case

(Reuters) July 12, 2018 - A Missouri jury on Thursday ordered Johnson & Johnson to pay a record $4.69 billion to 22 women who alleged the company’s talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer.

read article

New Method Reveals How Well Cancer Drugs Hit Their Targets

(Francis Crick Institute [UK]) July 12, 2018 - Scientists have developed a technique that allows them to measure how well cancer drugs reach their targets inside the body.

read article

ACA Credited with Earlier Diagnosis of Gynecologic Cancers in Young Women

(Johns Hopkins Medicine) July 11, 2018 - The gains in insurance coverage with the Patient Protection and Affordable Care Act (ACA) have already translated into improved health for young women with gynecologic cancers, who are getting diagnosed at earlier stages of their disease because of ACA benefits.

read press release

Large Population Study Fails To Find Any Causal Link Between Assisted Reproduction And Ovarian Cancer Risk

(ESHRE 2018) July 3, 2018 - Following concerns over many years that hormonal stimulation of the ovaries necessary for IVF may increase the risk of ovarian cancer, a nationwide cohort study from Denmark has now concluded that any perceived increase in risk is actually a statistical bias resulting from vigilant diagnosis at the time of treatment.

read press release

Clovis Oncology Receives EMA Validation For Its Application For A New Indication For Rubraca® (Rucaparib) As Maintenance Treatment For Women With Recurrent Ovarian Cancer

(Markets Insider) July 5, 2018 - The filing is based on positive phase 3 ARIEL3 clinical trial data in which rucaparib significantly improved progression free survival (PFS) compared to placebo in all primary efficacy ovarian cancer patient populations; timing of validation by EMA may allow for a CHMP opinion on maintenance treatment by year-end 2018.

read article

Artificial Human Ovaries Created For First Time In Major Breakthrough For Infertile Women

(The Telegraph [UK]) July 2, 2018 - “Artificial” human ovaries have been created for the first time in a breakthrough that promises hope for infertile women.

read article

Artificial Ovary Could Help Young Cancer Patients Preserve Fertility

(CNN) July 1, 2018 - An artificial ovary -- the female sex organ that produces eggs -- may soon be achievable, say Danish researchers who have engineered a "scaffold" on which early-stage cells can develop into functional ovarian follicles, the small fluid-filled sacs that contain a woman's eggs. This represents further progress in preserving a woman's fertility from the impact of cancer treatments, experts say.

read article

Compugen Shares Surge 12% Premarket After FDA Lifts Clinical Hold On Cancer Treatment

(MarketWatch) July 2, 2018 - Compugen Ltd. shares climbed 12% in premarket trade Monday, after the Israeli biotech said the U.S. Food and Drug Administration has lifted a clinical hold on its investigational new drug (IND) application for COM701, an immuno-oncology therapeutic antibody.

read article

CAR-T Immunotherapies May Have a New Player

(UC San Diego Health) June 28, 2018 - Emerging CAR-T immunotherapies leverage modified versions of patient’s T-cells to target and kill cancer cells. In a new study, published June 28 online in Cell Stem Cell , researchers at University of California San Diego School of Medicine and University of Minnesota report that similarly modified natural killer (NK) cells derived from human induced pluripotent stem cells (iPSCs) also displayed heightened activity against a mouse model of ovarian cancer.

read press release

BRACAnalysis® CDx Identifies Patients Who Respond to Lynparza® in SOLO-1 Study

(NASDAQ) June 28, 2018 - Myriad Genetics, Inc., a worldwide leader in personalized medicine, today announced that the Company’s BRACAnalysis® CDx test identified responders to Lynparza®, AstraZeneca and Merck’s (known as MSD outside the US and Canada) PARP inhibitor, in the Phase III, SOLO-1 study.

read article

Lynparza Significantly Delays Disease Progression In Phase III 1st-Line SOLO-1 Trial For Ovarian Cancer

(AstraZeneca) June 27, 2018 - Lynparza met primary endpoint of progression-free survival in women with BRCA-mutated advanced ovarian cancer and showed a safety profile consistent with previous trials; AstraZeneca and MSD’s Lynparza is the only PARP inhibitor to demonstrate significant activity in the 1st-line maintenance setting.

read corporate press release

AstraZeneca, Merck Eye $1 Billion Boost From Cancer Drug Success

(Reuters) June 27, 2018 - AstraZeneca’s oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.

read article

Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies

(Morningstar) June 26, 2018 - Arcus Biosciences, Inc. and Infinity Pharmaceuticals, Inc. today announced that they have entered into a clinical collaboration to evaluate two triple combination therapies in selected tumor types which typically show minimal response to checkpoint inhibition monotherapy.

read article

ASCO 2018: Large Study of DNA Mismatch Repair Genes Determines Mutation Frequency in Several Types of Cancer

(ESMO) June 20, 2018 - Results from a study evaluating the relationship between the number of somatic mutations (SMs) in four mismatch repair (MMR) genes and the microsatellite instability (MSI) phenotype showed specific mutations in DNA repair genes associated with younger age, and specific cancer types.

read article

ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer

(StreetInsider) June 18, 2018 - ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead program, mirvetuximab soravtansine.

read article

MD Anderson, Houston Methodist Scientists Detect New Ovarian Cancer Target

(MD Anderson) June 13, 2018 - The study opens a new potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.

read press release

FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery

(Genentech) June 13, 2018 - Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection.

read corporate press release

Paxman Announces FDA Clearance For An Expanded Indication Of Its Scalp Cooling System In The US

(Paxman) June 11, 2018 - PAXMAN’s advanced scalp cooling system has now been cleared by the US Food and Drug Administration (FDA) for use during treatment of patients with solid tumors.

read corporate press release

Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930

(NASDAQ) June 12, 2018 - Surface Oncology today announced the initiation of a Phase I trial of SRF373, a fully human antibody targeting CD73. SRF373, also known as NZV930, is the second of Surface's immunotherapies to advance into the clinic this year.

read article
Next Page